IQVIAIQV
Market Cap: $44.3B
About: IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Employees: 88,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
35% more repeat investments, than reductions
Existing positions increased: 428 | Existing positions reduced: 318
3% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 94
0% more funds holding
Funds holding: 991 [Q1] → 994 (+3) [Q2]
2.31% less ownership
Funds ownership: 88.94% [Q1] → 86.63% (-2.31%) [Q2]
18% less capital invested
Capital invested by funds: $40.9B [Q1] → $33.4B (-$7.51B) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 16 [Q1] → 12 (-4) [Q2]
41% less call options, than puts
Call options by funds: $170M | Put options by funds: $287M
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
12 analyst ratings
RBC Capital Sean Dodge 55% 1-year accuracy 24 / 44 met price target | 13%upside $275 | Outperform Initiated | 4 Sept 2024 |
JP Morgan Anne Samuel 57% 1-year accuracy 8 / 14 met price target | 18%upside $288 | Overweight Maintained | 5 Aug 2024 |
Jefferies David Windley 50% 1-year accuracy 7 / 14 met price target | 0%downside $242 | Hold Downgraded | 24 Jul 2024 |
Morgan Stanley Tejas Savant 69% 1-year accuracy 11 / 16 met price target | 15%upside $280 | Overweight Maintained | 23 Jul 2024 |
UBS Dan Brennan 61% 1-year accuracy 17 / 28 met price target | 23%upside $300 | Buy Maintained | 23 Jul 2024 |
Financial journalist opinion
Based on 6 articles about IQV published over the past 30 days